BrainChild Bio Raises $116 Million for CNS CAR-T
BrainChild Bio raised a $116 million Series A to fund BCB-276, a B7-H3-directed autologous CAR-T therapy administered into cerebrospinal fluid, through the pivotal-intent Phase II ILLUMINATE study in newly diagnosed diffuse intrinsic pontine glioma….
